Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

NCT02453711 on ClinicalTrials.gov · last registry update 2020-04-17

An unusually large phase 2: 957 participants, more than double the 110 typical for the stage. The sponsor logged completion for 30 March 2017. Primary outcome, as filed: Relative Change in Body Weight (%). semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 957
Started: 2015-10-01
Primary completion: 2017-03-30 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Relative Change in Body Weight (%)

Conditions studied

Metabolism and Nutrition Disorder · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.